No specific treatment is available for EGFR-TKI-associated ILD, and supportive therapy largely includes oxygen, corticosteroids, or assisted ventilation, with an approximate 30%–40% mortality of the disease. The gene discussed is EGFR; the disease is interstitial lung disease.